JP2012102105A5 - - Google Patents

Download PDF

Info

Publication number
JP2012102105A5
JP2012102105A5 JP2011265649A JP2011265649A JP2012102105A5 JP 2012102105 A5 JP2012102105 A5 JP 2012102105A5 JP 2011265649 A JP2011265649 A JP 2011265649A JP 2011265649 A JP2011265649 A JP 2011265649A JP 2012102105 A5 JP2012102105 A5 JP 2012102105A5
Authority
JP
Japan
Prior art keywords
peptide
antigen
peptide according
hla
cytotoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011265649A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012102105A (ja
JP5789820B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012102105A publication Critical patent/JP2012102105A/ja
Publication of JP2012102105A5 publication Critical patent/JP2012102105A5/ja
Application granted granted Critical
Publication of JP5789820B2 publication Critical patent/JP5789820B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2011265649A 2005-02-28 2011-12-05 血管内皮増殖因子受容体1に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン Expired - Fee Related JP5789820B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65752705P 2005-02-28 2005-02-28
US60/657,527 2005-02-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007529685A Division JP4931154B2 (ja) 2005-02-28 2006-02-17 血管内皮増殖因子受容体1に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン

Publications (3)

Publication Number Publication Date
JP2012102105A JP2012102105A (ja) 2012-05-31
JP2012102105A5 true JP2012102105A5 (enExample) 2013-02-28
JP5789820B2 JP5789820B2 (ja) 2015-10-07

Family

ID=36581423

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007529685A Expired - Fee Related JP4931154B2 (ja) 2005-02-28 2006-02-17 血管内皮増殖因子受容体1に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン
JP2010129158A Active JP4843095B2 (ja) 2005-02-28 2010-06-04 血管内皮増殖因子受容体1に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン
JP2011265649A Expired - Fee Related JP5789820B2 (ja) 2005-02-28 2011-12-05 血管内皮増殖因子受容体1に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2007529685A Expired - Fee Related JP4931154B2 (ja) 2005-02-28 2006-02-17 血管内皮増殖因子受容体1に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン
JP2010129158A Active JP4843095B2 (ja) 2005-02-28 2010-06-04 血管内皮増殖因子受容体1に由来するエピトープ・ペプチドおよびこれらのペプチドを含むワクチン

Country Status (10)

Country Link
US (4) US7919099B2 (enExample)
EP (4) EP2289533B1 (enExample)
JP (3) JP4931154B2 (enExample)
CY (1) CY1112867T1 (enExample)
DK (3) DK2095822T3 (enExample)
ES (3) ES2435650T3 (enExample)
PL (3) PL2095822T3 (enExample)
PT (3) PT2095822E (enExample)
SI (3) SI1855707T1 (enExample)
WO (1) WO2006093030A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1548032T1 (sl) 2002-09-12 2009-10-31 Oncotherapy Science Inc KDR peptidi in cepiva, ki obsegajo le-te
PL2119447T3 (pl) * 2007-02-16 2013-08-30 Oncotherapy Science Inc Terapia szczepionkowa przeciwko neowaskularyzacji naczyniówkowej
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
EP2823824A4 (en) * 2012-03-09 2015-09-16 Oncotherapy Science Inc PHARMACEUTICAL COMPOSITION CONTAINING PEPTIDE
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
US20200147194A1 (en) * 2017-05-19 2020-05-14 Keio University Peptide vaccine and peptide vaccine composition for cranial nerve disease
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH0418667A (ja) * 1989-07-05 1992-01-22 Tohoku Nippon Denki Software Kk 自動配送システム
JPH0350140A (ja) * 1989-07-18 1991-03-04 Seiko Epson Corp 分布屈折率レンズの製造方法
DK0694042T3 (da) * 1993-03-25 2005-02-14 Merck & Co Inc Inhibitor af vaskulær endothelcellevækstfaktor
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
EP0841945B1 (en) 1995-08-03 2006-03-08 Rijksuniversiteit te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
CA2262006A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6200954B1 (en) * 1998-09-04 2001-03-13 National University Of Singapore Small peptides having potent anti-angiogenic activity
WO2002072627A2 (en) * 2001-03-09 2002-09-19 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
FI110549B (fi) 2001-06-29 2003-02-14 Nokia Corp Menetelmä ja järjestely liikkeen määrittämiseksi
US20030157101A1 (en) 2001-11-15 2003-08-21 Carlo Gambacorti-Passerini Immunogenic ALK peptides
WO2003050140A1 (fr) 2001-12-10 2003-06-19 Kyogo Itoh Antigenes tumoraux
CU23178A1 (es) 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
JP2004018667A (ja) 2002-06-17 2004-01-22 National Institute Of Advanced Industrial & Technology 高分子化合物膜の表面における炭酸カルシウム被膜の製造方法
JP4406607B2 (ja) 2002-08-26 2010-02-03 オンコセラピー・サイエンス株式会社 ペプチド及びこれを含む医薬
SI1548032T1 (sl) * 2002-09-12 2009-10-31 Oncotherapy Science Inc KDR peptidi in cepiva, ki obsegajo le-te
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization

Similar Documents

Publication Publication Date Title
JP2012102105A5 (enExample)
JP2012176978A5 (enExample)
JP2010500399A5 (enExample)
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
JP2014534202A5 (enExample)
RU2016146801A (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
RU2011110504A (ru) Эпитопные пептиды inhbb и вакцины, содержащие данные пептиды
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
JP2015214545A5 (enExample)
JP2016502551A5 (enExample)
JP2012500001A5 (enExample)
JP2018509935A5 (enExample)
JP2015517488A5 (enExample)
ES2673556T3 (es) Vacunas para el VHS-2
JP2013507907A5 (enExample)
SV2016005145A (es) Polipéptidos cíclicos para el tratamiento de la insuficiencia cardiaca
JP2012115277A5 (enExample)
JP2019531293A5 (enExample)
JP2008530975A5 (enExample)
JP2015533791A5 (enExample)
JP2012529293A5 (enExample)
JP2014139185A5 (enExample)